Abstract | BACKGROUND: METHODS: RESULTS: CONCLUSION: Taken together, our results suggest that MitoQ may have potential as a novel therapeutic agent for the treatment of acute phases of inflammatory bowel disease.
|
Authors | Amarjargal Dashdorj, K R Jyothi, Sangbin Lim, Ara Jo, Minh Nam Nguyen, Joohun Ha, Kyung-Sik Yoon, Hyo Jong Kim, Jae-Hoon Park, Michael P Murphy, Sung Soo Kim |
Journal | BMC medicine
(BMC Med)
Vol. 11
Pg. 178
(Aug 06 2013)
ISSN: 1741-7015 [Electronic] England |
PMID | 23915129
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antioxidants
- Carrier Proteins
- Inflammasomes
- Inflammation Mediators
- NLR Family, Pyrin Domain-Containing 3 Protein
- Nlrp3 protein, mouse
- Organophosphorus Compounds
- Reactive Oxygen Species
- Ubiquinone
- mitoquinone
|
Topics |
- Animals
- Antioxidants
(pharmacology, therapeutic use)
- Carrier Proteins
(antagonists & inhibitors, physiology)
- Cells, Cultured
- Colitis
(drug therapy, metabolism, pathology)
- Disease Models, Animal
- Drug Delivery Systems
(methods)
- Female
- Humans
- Inflammasomes
(antagonists & inhibitors, physiology)
- Inflammation Mediators
(antagonists & inhibitors, physiology)
- Male
- Mice
- Mice, Inbred BALB C
- Mitochondria
(drug effects, metabolism, pathology)
- NLR Family, Pyrin Domain-Containing 3 Protein
- Organophosphorus Compounds
(administration & dosage, therapeutic use)
- Reactive Oxygen Species
(metabolism)
- Ubiquinone
(administration & dosage, analogs & derivatives, therapeutic use)
|